MarkAPilkintonMD

Infectious Disease • Nashville, TN

Physician

Join to view full profile

Are you Dr. Pilkinton?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1161 21st Ave S
Nashville, TN 37232
Phone+1 615-322-2035

Fax+1 615-343-6160

Summary

Dr. Mark Pilkinton, MD is an infectious disease specialist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee. He is affiliated with Ascension Saint Thomas.

Education & Training

Vanderbilt University Medical CenterFellowship, Infectious Disease, 2011 - 2013
Vanderbilt University Medical CenterResidency, Internal Medicine, 2009 - 2011
University of Illinois College of MedicineClass of 2009

Certifications & Licensure

TN State Medical License 2013 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants Start of enrollment: 2022 Mar 01
Withdrawn
Phase 1

Publications & Presentations

PubMed

7 citations
Predictors of HIV rebound differ by timing of antiretroviral therapy initiation.
Jonathan Z Li, Meghan Melberg, Autumn Kittilson, Mohamed Abdel-Mohsen, Yijia Li
JCI Insight. 2024-02-08
1 citations
Tracking of activated cTfh cells following sequential influenza vaccinations reveals transcriptional profile of clonotypes driving a vaccine-induced immune response.
Jennifer Currenti, Joshua Simmons, Jared Oakes, Silvana Gaudieri, Christian M Warren
Frontiers in Immunology. 2023-01-01
1 citations
The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells.
Mona Mashayekhi, Celestine N Wanjalla, Christian M Warren, Joshua D Simmons, Kakali Ghoshal
Prostaglandins & Other Lipid Mediators. 2022-02-01

Press Mentions

Gene Identified That Increases Risk of Antibiotic ReactionMarch 8th, 2019
Research Reveals Link Between Immunity, DiabetesSeptember 13th, 2018
Flu Vaccine Response in Older AdultsJanuary 25th, 2017